What Is Long COVID?
Long COVID is defined by the CDC as new, recurring, or ongoing health problems that appear 4 or more weeks after initial SARS-CoV-2 infection. It is also called Post-Acute Sequelae of SARS-CoV-2 (PASC) or post-COVID conditions. Critically, Long COVID can follow any severity of acute illness — including infections that were mild or even asymptomatic. Research also shows that each reinfection carries additional Long COVID risk, making prevention of repeat infections an important ongoing health concern.
The WHO estimates that 10–20% of people infected with SARS-CoV-2 experience Long COVID. The NIH has committed over $1.15 billion to the RECOVER Initiative — the largest coordinated study of Long COVID to date — enrolling more than 17,000 participants across 200+ research sites.
Symptoms
Long COVID encompasses more than 200 reported symptoms. The NIH RECOVER Initiative identified the following 12 symptoms most predictive of Long COVID at 6 months post-infection:[LC1]
Most Discriminating
- Post-exertional malaise (PEM) — symptom worsening after physical or mental effort
- Fatigue — often severe and not relieved by rest
- Brain fog — difficulty concentrating, memory problems, cognitive slowing
Commonly Reported
- Shortness of breath or difficulty breathing
- Heart palpitations or rapid heartbeat
- Dizziness upon standing (orthostatic intolerance)
- Headache
- Sleep disturbances
- Joint or muscle pain
- Persistent cough
- Changes in smell or taste (parosmia, anosmia)
- Anxiety or depression
Risk Factors
The NIH RECOVER Initiative and other large studies have identified several factors associated with increased Long COVID risk:[LC2]
- Female sex — consistently higher rates in most cohort studies
- Older age — though Long COVID affects all ages including children
- Prior health conditions — particularly autoimmune conditions, asthma, and mood disorders
- Severity of acute illness — hospitalization predicts higher risk, though mild cases also lead to Long COVID
- High viral load — higher acute RNA levels associated with persistence
- Reinfection — each infection carries additional Long COVID risk; see our COVID reinfection guide for the cumulative risk evidence
- Unvaccinated status — vaccination reduces Long COVID risk by approximately 50%
Proposed Mechanisms
Researchers have proposed several (likely overlapping) mechanisms. No single explanation accounts for all Long COVID phenotypes:
- Viral persistence — SARS-CoV-2 RNA and protein detected in gut, lymph nodes, and other tissues months post-infection
- Immune dysregulation — persistent inflammation, activated T-cells, elevated cytokines, and autoantibodies
- Microbiome disruption — gut dysbiosis correlated with Long COVID symptoms
- Reactivation of latent viruses — Epstein-Barr virus reactivation observed in a subset of Long COVID patients
- Endothelial damage and microclots — microthrombi affecting tissue perfusion, particularly relevant for brain fog and fatigue
- Autonomic dysfunction — POTS (Postural Orthostatic Tachycardia Syndrome) seen in a significant Long COVID subset
Treatment & Management
No FDA-approved treatment exists specifically for Long COVID as of 2026. Management is symptom-based and multidisciplinary. Several clinical trials are underway:
- Paxlovid (nirmatrelvir/ritonavir) — being studied for Long COVID based on the viral persistence hypothesis; RECOVER-VITAL trial ongoing
- Low-dose naltrexone — used off-label for immune modulation and fatigue; early observational evidence
- Antihistamines (famotidine, cetirizine) — some patients report improvement, possibly related to mast cell activation
- Cognitive rehabilitation — for brain fog and cognitive symptoms
- Exercise caution (pacing) — research from the NIH RECOVER Initiative and the ME/CFS literature indicates that vigorous exercise can worsen PEM; pacing, a structured approach to energy management, is the evidence-based standard of care for this symptom
- POTS management — autonomic dysfunction in Long COVID is typically evaluated by a cardiologist or autonomic specialist; management strategies documented in the literature include increased fluid and sodium intake and compression garments, while pharmacological options such as beta-blockers are prescribed and monitored by a clinician
References
- Thaweethai T, et al. "Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection." JAMA, 2023. doi:10.1001/jama.2023.8823
- Bowe B, et al. "Long COVID after breakthrough SARS-CoV-2 infection." Nature Medicine, 2022. doi:10.1038/s41591-022-01840-0
